ZOM - Zomedica Pharmaceuticals Corp Stock Price, Fair Value and News

0.13USD0.00 (0.00%)Market Closed

Market Summary

USD0.130.00

Market Closed

0.00%

ZOM Stock Price

View Fullscreen

ZOM RSI Chart

ZOM Valuation

Market Cap

127.4M

Price/Earnings (Trailing)

-3.69

Price/Sales (Trailing)

5.06

EV/EBITDA

-3.29

Price/Free Cashflow

-7.73

ZOM Price/Sales (Trailing)

ZOM Profitability

Operating Margin

68.76%

EBT Margin

-142.38%

Return on Equity

-14.39%

Return on Assets

-13.64%

Free Cashflow Yield

-12.93%

ZOM Fundamentals

ZOM Revenue

Revenue (TTM)

25.2M

Rev. Growth (Yr)

19.17%

Rev. Growth (Qtr)

15.6%

ZOM Earnings

Earnings (TTM)

-34.5M

Earnings Growth (Yr)

-697.47%

Earnings Growth (Qtr)

-4.5K%

Breaking Down ZOM Revenue

Last 7 days

8.3%

Last 30 days

-7.1%

Trailing 12 Months

-35.8%

How does ZOM drawdown profile look like?

ZOM Financial Health

Current Ratio

11.06

ZOM Investor Care

Diluted EPS (TTM)

-0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	20.7M	22.4M	24.0M	25.2M
2022	7.8M	11.5M	15.2M	18.9M
2021	1.1M	2.1M	3.1M	4.1M
2020	516.5K	0	274.7K	32.9K
2019	2.0M	0	1.9M	758.3K
2018	1.4M	0	1.3M	1.6M
2017	1.3M	0	1.3M	1.3M
2016	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Zomedica Pharmaceuticals Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 15, 2023	powers johnny d	bought	16,500	0.165	100,000	-
Nov 17, 2023	powers johnny d	bought	16,600	0.166	100,000	-
Nov 17, 2023	heaton larry c ii	bought	16,600	0.166	100,000	ceo
Nov 15, 2023	powers johnny d	bought	25,950	0.173	150,000	-
May 26, 2023	heaton larry c ii	bought	19,090	0.1909	100,000	ceo
May 25, 2023	powers johnny d	bought	19,340	0.1934	100,000	-
Nov 18, 2021	powers johnny d	bought	112,500	0.45	250,000	-
Jun 30, 2021	cohen robert	sold	-447,343	0.8227	-543,750	ceo
Jun 30, 2021	cohen robert	acquired	125,062	0.23	543,750	ceo

Which funds bought or sold ZOM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Center for Financial Planning, Inc.	unchanged	-	-271	730	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-77.1	-72,742	14,574	-%
Apr 25, 2024	Bogart Wealth, LLC	new	-	26.00	26.00	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	reduced	-63.79	-18,000	6,000	-%
Apr 24, 2024	Spire Wealth Management	reduced	-6.07	57.00	730	-%
Apr 22, 2024	Kessler Investment Group, LLC	unchanged	-	-18.00	50.00	-%
Apr 22, 2024	Reitz Capital Advisors LLC	unchanged	-	-	4,605	0.01%
Apr 19, 2024	IVC Wealth Advisors LLC	sold off	-100	-4,004	-	-%
Apr 19, 2024	Tradewinds Capital Management, LLC	unchanged	-	-6.00	15.00	-%
Apr 18, 2024	Hexagon Capital Partners LLC	unchanged	-	-16.00	41.00	-%

Are Funds Buying or Selling ZOM?

Are funds buying ZOM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ZOM

No. of Funds

Unveiling Zomedica Pharmaceuticals Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2021	rowe jeffrey m	2.2%	12,652,980	SC 13G/A
Jan 29, 2021	intracoastal capital, llc	2.4%	13,694,000	SC 13G/A
Jan 05, 2021	sabby management, llc	2.24%	12,633,334	SC 13G/A
Jul 02, 2020	equidebt llc	2.70%	9,918,913	SC 13D/A
Jun 05, 2020	armistice capital, llc	4.99%	15,315,997	SC 13G
Jun 04, 2020	intracoastal capital, llc	5.0%	15,487,333	SC 13G
Feb 21, 2020	armistice capital, llc	4.99%	6,768,444	SC 13G
Feb 12, 2020	sabby management, llc	6.47%	8,333,334	SC 13G
Jan 24, 2020	equidebt llc	8.19%	8,845,913	SC 13D
Dec 04, 2019	solensky gerald jr	36.7%	40,250,936	SC 13D/A

Recent SEC filings of Zomedica Pharmaceuticals Corp

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 04, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 15, 2024	8-K	Current Report
Feb 29, 2024	8-K	Current Report
Feb 20, 2024	DEFA14A	DEFA14A
Feb 06, 2024	DEFA14A	DEFA14A
Jan 31, 2024	DEFA14A	DEFA14A
Jan 26, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Zomedica Pharmaceuticals Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	352.0B	85.2B	-7.49%	-10.35%	10.01	4.13	6.46%	95.94%
MRK	332.3B	60.1B	-0.42%	13.93%	910.36	5.53	1.40%	-97.49%
AMGN	144.7B	28.2B	-5.70%	12.33%	21.54	5.13	7.09%	2.52%
PFE	143.3B	46.5B	-8.64%	-34.49%	-103.22	3.08	42.59%	-114.62%
GILD	81.5B	27.1B	-10.34%	-21.65%	14.4	3.01	-0.60%	23.36%
TEVA	15.4B	15.8B	-4.37%	61.97%	-26.83	0.97	6.17%	76.47%
MID-CAP
PRGO	4.3B	4.7B	1.49%	-12.83%	-340.71	0.93	4.58%	90.97%
ALKS	4.1B	1.7B	-9.36%	-12.84%	11.6	2.48	49.61%	324.78%
BHC	3.2B	8.8B	-16.97%	22.33%	-5.38	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-5.51%	13.03%	14.38	3.07	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-28.23%	-25.52%	-3.91	1.85	24.65%	80.36%
TXMD	21.5M	1.3M	-17.33%	-48.76%	-2.09	16.47	-98.14%	-109.18%
ACRX	17.8M	-	-4.55%	55.56%	-0.97	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	8.11%	-93.94%	-0.19	0.14	80.00%	43.08%
ACOR	906.7K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Zomedica Pharmaceuticals Corp News

Latest updates

Zomedica Pharmaceuticals Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q1	2019Q4	2019Q3	2019Q1	2018Q4	2018Q3	2018Q1
Revenue	15.6%	7,337,000	6,347,000	6,020,000	5,482,000	6,157,000	4,776,000	4,246,000	3,751,000	2,506,000	1,261,000	16,000	14,000	17,619	21,238	290,682	284,960	279,237	758,298	533,091	293,484	371,947
Cost Of Revenue	14.1%	2,264,000	1,985,000	1,972,000	1,647,000	1,762,000	1,265,000	1,240,000	1,011,000	1,019,500	18,000	36,000	6,000	-	-	-	-	-	-	-	-	-
Gross Profit	16.3%	5,073,000	4,362,000	4,048,000	3,835,000	4,395,000	3,511,000	3,006,000	2,740,000	3,061,000	5,000	-20,000	8,000	-	-	-	-	-	-	-	-	-
S&GA Expenses	-178.7%	-2,620,000	3,328,000	9,931,000	10,429,000	20,260,500	3,735,000	8,567,000	6,703,000	8,143,000	6,124,000	5,038,000	3,468,000	3,307,608	2,298,330	1,703,443	1,494,406	1,377,252	3,212,357	1,278,118	834,570	1,160,171
R&D Expenses	257.5%	3,099,500	867,000	859,000	918,000	693,000	1,215,000	319,000	351,000	683,000	289,000	271,000	412,000	820,884	2,702,103	630,066	789,946	962,463	7,531,375	6,551,821	630,371	600,341
EBITDA Margin	-Infinity%	-1.38	-	-0.90	-1.01	-1.00	-1.35	-1.85	-2.62	-4.94	-6.10	-8.44	-17.16	-505	-	-	-	-	-	-	-	-
Interest Expenses	-100.8%	-500	64,000	62,000	50,000	-	-	-	107,000	-27,554	-	6,054	55,000	40.50	-	651	-	-	6,174	-	-	-
Income Taxes	123.9%	458,500	-1,920,000	-77,000	208,000	-1,049,000	-657,000	-382,000	-278,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-810.3%	-21,946,500	-2,411,000	-5,326,000	-6,177,000	-3,858,500	-5,652,000	-5,655,000	-4,215,000	-5,623,500	-6,346,000	-4,711,000	-4,037,000	-4,173,202	-4,979,975	-2,450,618	-2,857,039	-2,845,679	-11,676,908	-8,421,682	-1,910,278	-2,171,328
EBT Margin	-92.3%	-1.42	-0.74	-0.94	-1.03	-1.02	-1.39	-1.89	-2.67	-5.01	-6.20	-8.59	-17.49	-	-	-	-	-	-	-	-	-
Net Income	-4463.1%	-22,405,000	-491,000	-5,249,000	-6,385,000	-2,809,500	-4,995,000	-5,273,000	-3,937,000	-3,290,500	-6,346,000	-4,711,000	-4,037,000	-4,173,202	-4,979,975	-2,450,618	-2,857,039	-2,845,679	-11,676,908	-8,421,682	-1,910,278	-2,171,328
Net Income Margin	-120.4%	-1.37	-0.62	-0.87	-0.94	-0.90	-1.15	-1.63	-2.33	-4.45	-6.20	-8.59	-17.49	-	-	-	-	-	-	-	-	-
Free Cashflow	-57.1%	-5,130,000	-3,265,000	-3,706,000	-4,370,000	-2,587,000	-3,202,000	-4,114,000	-2,554,000	-4,953,000	-5,051,000	-1,766,000	-2,653,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.9%	253	275	275	280	280	282	275	278	280	278	280	280	66.00	57.00	33.00	5.00	4.00	7.00	9.00	6.00	6.00
Current Assets	-13.4%	100	115	140	130	124	127	195	198	200	275	277	279	64.00	53.00	30.00	2.00	2.00	4.00	7.00	3.00	4.00
Cash Equivalents	-40.5%	13.00	22.00	28.00	8.00	27.00	45.00	187	192	195	271	276	277	62.00	52.00	29.00	1.00	1.00	2.00	7.00	2.00	2.00
Inventory	37.1%	5.00	4.00	4.00	3.00	3.00	2.00	5.00	4.00	3.00	1.00	1.00	0.00	-	-	-	-	-	-	-	-	-
Net PPE	25.3%	10.00	8.00	7.00	7.00	7.00	7.00	2.00	1.00	1.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	-16.5%	62.00	74.00	64.00	64.00	64.00	64.00	6.00	43.00	43.00	43.00	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-7.0%	13.00	14.00	15.00	17.00	12.00	14.00	9.00	9.00	10.00	6.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	-	-	-	-
Current Liabilities	34.0%	9.00	7.00	7.00	9.00	8.00	7.00	4.00	4.00	4.00	5.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	8.00	2.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	-	-	-	-	-	-	-	-
Shareholder's Equity	-8.0%	240	261	259	263	267	269	266	269	271	272	276	278	51.00	88.00	30.00	2.00	2.00	5.00	8.00	-	4.00
Retained Earnings	-15.1%	-170	-148	-148	-142	-136	-133	-128	-123	-119	-116	-109	-105	-68.97	-64.80	-59.82	-54.51	-52.06	-49.20	-46.36	-43.95	-32.27
Additional Paid-In Capital	3.8%	30.00	29.00	27.00	25.00	24.00	22.00	14.00	11.00	9.00	7.00	6.00	5.00	15.00	18.00	9.00	5.00	4.00	4.00	3.00	3.00	1.00
Shares Outstanding	0%	980	980	980	980	980	980	980	980	980	949	974	890	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	213	-	-	-	803	-	-	-	82.00	-	-	-	12.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-65.7%	-5,015	-3,027	-3,676	-4,257	-2,383	-2,770	-4,046	-2,471	-4,903	-4,997	-1,738	-2,638	-2,683	-5,662	-5,720	-2,173	-1,286	-3,910	-8,436	-2,581	-3,328
Share Based Compensation	-33.8%	1,105	1,668	1,725	1,765	1,439	1,919	2,492	2,041	2,589	1,438	1,782	1,283	1,177	188	136	155	-	198	-	2,341	-
Cashflow From Investing	-22.6%	-3,829	-3,123	23,321	-14,792	-15,351	-138,886	-1,437	-206	-71,582	-201	-124	-18.00	-1.18	-613*	-	1,008	-29.93	-582	-5.48	-69.09	-13.63
Cashflow From Financing	-	-	-	-	-	-	8.00	-	-	23.00	400	1,470	217,266	12,643	28,593	33,327	2,152	-81.00	-1.41	11,967	3,007	4,755

ZOM Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Consolidated Statements of Operations and Comprehensive Loss
Net revenue	$ 25,186	$ 18,930
Cost of revenue	7,868	5,462
Gross profit	17,318	13,468
Expenses
General and administrative	29,029	22,934
Research and development	5,744	2,578
Selling and marketing	14,137	9,879
Loss from operations	(31,592)	(21,923)
Interest income	5,458	2,701
Interest expense	(175)	(1)
Gain on disposal of assets	24	1
Other income (loss)	2,080	(7)
Impairment expense	(11,683)
Foreign exchange gain (loss)	28	(152)
Loss before income taxes	(35,860)	(19,381)
Income tax benefit	(1,331)	(2,366)
Net loss	(34,529)	(17,015)
Unrealized gain (loss), change in fair value of available-for-sale securities, net of tax	936	(869)
Change in foreign currency translation	(45)	24
Net loss and comprehensive loss	$ (33,638)	$ (17,860)
Weighted average number of common shares - basic (in shares)	979,949,668	979,949,668
Weighted average number of common shares - diluted (in shares)	979,949,668	979,949,668
Loss per share - basic (in dollars per share)	$ (0.035)	$ (0.017)
Loss per share - diluted (in dollars per share)	$ (0.035)	$ (0.017)

ZOM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 12,952	$ 27,399
Available-for-sale securities	77,545	87,693
Trade receivables, net	1,197	596
Inventory, net	5,123	2,746
Prepaid expenses and deposits	2,064	3,799
Other receivables	1,001	1,268
Total current assets	99,882	123,501
Prepaid expenses and deposits	250	188
Property and equipment, net	10,347	6,809
Construction in progress	12,481	692
Right-of-use asset	2,466	1,665
Goodwill	61,580	63,979
Intangible assets, net	55,364	41,799
Non current available-for-sale securities	10,005	40,712
Other assets	822	265
Total assets	253,197	279,610
Current liabilities
Accounts payable and accrued liabilities	7,668	6,698
Accrued income taxes	65	187
Current portion of lease obligations	916	641
Customer contract liabilities	276	207
Other current liabilities	107	78
Total current liabilities	9,032	7,811
Lease obligations	1,814	1,097
Deferred tax liabilities	1,138	1,245
Customer contract liabilities	252	182
Other liabilities	944	1,883
Total liabilities	13,180	12,218
Commitments and contingencies (Note 16)
Shareholders' equity
Unlimited common shares, no par value; 979,949,668 issued and outstanding at December 31, 2023 and December 31, 2022	380,973	380,973
Additional paid-in capital	29,929	23,666
Accumulated deficit	(170,933)	(136,404)
Accumulated comprehensive income (loss)	48	(843)
Total shareholders' equity	240,017	267,392
Total liabilities and shareholders' equity	$ 253,197	$ 279,610

About Zomedica Pharmaceuticals Corp

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

CEO	Mr. Larry C. Heaton II
WEBSITE	zomedica.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	85

Zomedica Pharmaceuticals Corp Frequently Asked Questions

What is the ticker symbol for Zomedica Pharmaceuticals Corp? What does ZOM stand for in stocks?

ZOM is the stock ticker symbol of Zomedica Pharmaceuticals Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zomedica Pharmaceuticals Corp (ZOM)?

As of Fri Apr 26 2024, market cap of Zomedica Pharmaceuticals Corp is 127.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZOM stock?

You can check ZOM's fair value in chart for subscribers.

What is the fair value of ZOM stock?

You can check ZOM's fair value in chart for subscribers. The fair value of Zomedica Pharmaceuticals Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zomedica Pharmaceuticals Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZOM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zomedica Pharmaceuticals Corp a good stock to buy?

The fair value guage provides a quick view whether ZOM is over valued or under valued. Whether Zomedica Pharmaceuticals Corp is cheap or expensive depends on the assumptions which impact Zomedica Pharmaceuticals Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZOM.

What is Zomedica Pharmaceuticals Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, ZOM's PE ratio (Price to Earnings) is -3.69 and Price to Sales (PS) ratio is 5.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZOM PE ratio will change depending on the future growth rate expectations of investors.